Editors:
Provides a comprehensive review of the new agents for treatment of chemotherapy-induced nausea and vomiting
Provides a detailed description of new uses of current agents for treatment of chemotherapy-induced nausea and vomiting
Discusses an integration of the available agents for treatment of chemotherapy-induced nausea and vomiting in clinical practice
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (12 chapters)
-
Front Matter
About this book
CINV is one of the most feared treatment related toxicities. Patient surveys for the past thirty years consistently demonstrate patients’ perception of deterioration in quality of life due to chemotherapy treatments. The introduction of the antiemetics, serotonin 5-HT3 receptor antagonists and the neurokinin-1 receptor antagonists, have improved the control of chemotherapy-induced emesis, but the treatment of chemotherapy-induced nausea remains a significant clinical problem. Patients continue to have quality of life issues which prevent normal functioning during active treatment. New agents such as the second generation 5-HT3 receptor antagonist palonosetron and the new neuroknin-1 receptor antagonists rolapitant and netupitant are being introduced into clinical practice, and it is anticipated that these new agents will improve the control of CINV. Agents such as olanzapine (a FDA approved anti-psychotic), gabapentin (a FDA approved neuroleptic), and ginger (a food additive), which have been used primarily for other indications, are now being tested as potential, effective antiemetics.
This work represents the first available comprehensive summary that details all new antiemetic agents and, particularly, their clinical role in treating patients; an important reference for practitioners seeking to improve the quality of life of patients undergoing chemotherapy.
Editors and Affiliations
-
Indiana University School of Medicine, South Bend, USA
Rudolph M. Navari
About the editor
Dr. Navari's research interests include supportive care in clinical oncology, development of antiemetics, palliative care, and the doctor-patient relationship in clinical oncology. He has published over one hundred and thirty peer reviewed articles, with the most recent dealing with supportive care issues in clinical oncology.
Bibliographic Information
Book Title: Management of Chemotherapy-Induced Nausea and Vomiting
Book Subtitle: New Agents and New Uses of Current Agents
Editors: Rudolph M. Navari
DOI: https://doi.org/10.1007/978-3-319-27016-6
Publisher: Adis Cham
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer International Publishing Switzerland 2016
Hardcover ISBN: 978-3-319-27014-2Published: 01 February 2016
Softcover ISBN: 978-3-319-80058-5Published: 30 March 2018
eBook ISBN: 978-3-319-27016-6Published: 25 January 2016
Edition Number: 1
Number of Pages: VIII, 181
Number of Illustrations: 9 b/w illustrations, 8 illustrations in colour
Topics: Oncology, Pharmacology/Toxicology, Pharmacotherapy